Rapid Micro Biosystems Inc (RPID)

Rapid Micro Biosystems reports record 2025 performance, raises 2026 outlookMarch 12, 2026 11:47 AM
IH Market News
Rapid Micro Biosystems (NASDAQ:RPID) reported record results for both the fourth quarter and full year of 2025 on March 12, 2026, as strong demand for its Growth Direct platform drove higher product and recurring revenue.Fourth-quarter revenue climbed 37% year-over-year to $11.3 million, while full-year revenue increased 20% to $33.6 million. Despite the revenue growth, the company recorded a wider quarterly net loss of $12.5 million.The company pointed to strong commercial momentum during the year, including a record multi-system Growth Direct order from Amgen in late 2025 and another significant multi-system order from Samsung Biologics in early 2026.Looking ahead, Rapid Micro Biosystems expects 2026 revenue to range between $37 million and $41 million. The company also anticipates improved gross margins and plans to install between 30 and 38 Growth Direct systems during the year, reflecting increasing global adoption of its technology even as the business continues to operate at a loss.During 2025, the company installed 28 Growth Direct systems and achieved a modest positive gross margin for the full year. Operating expenses were tightly managed, although inventory write-offs weighed on margins in the fourth quarter.Rapid Micro Biosystems ended 2025 with approximately $39 million in cash and an additional $25 million available under an undrawn debt facility. The company said this liquidity will support its strategy of expanding system placements, improving margins and advancing new product development as major biopharmaceutical companies increasingly adopt its automation platform.More about Rapid Micro BiosystemsRapid Micro Biosystems, Inc. is a life sciences technology company that develops automation solutions designed to improve manufacturing efficiency and accelerate the safe release of healthcare products. Its technology is used in the production of biologics, vaccines, cell and gene therapies and sterile injectable medicines.The company’s flagship Growth Direct system automates microbial quality control testing for large pharmaceutical manufacturing operations. By modernizing testing processes and bringing quality control closer to the manufacturing floor, the platform aims to improve speed, accuracy, regulatory compliance and overall operational efficiency.Rapid Micro Biosystems stock price

Original: Rapid Micro Biosystems reports record 2025 performance, raises 2026 outlook

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Source: GlobeNewswire Inc.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that Samsung Biologics (KRX: 207940.KS) has selected the Growth Direct® platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.
“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “The Growth Direct® improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”

Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges. It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.

To learn more about the Company and the Growth Direct® platform please visit: Rapid Micro Biosystems.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 184KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.